AI agent Robin proposed a retinal degeneration drug and validated it in the lab
FutureHouse's agent Robin autonomously went from literature review to drug selection for dry age-related macular degeneration in 2025. It proposed ripasudil, a ROCK inhibitor approved in Japan for glaucoma, and a lab test on RPE cells confirmed the predicted mechanism.
- Robin proposed ripasudil for dry age-related macular degeneration
- A lab test on RPE cells confirmed the predicted mechanism
- Earlier, Adam (2009) and Eve (2015) automated the cycle in yeast genetics and antimalarials
- Google unveiled a Gemini-based AI co-scientist for biomedicine in February 2025
Read next
Business